SPRB: OPCO frames RARE’s accelerated Genglycos approval as positive
SPRB OPCO says yesterday’s accelerated approval of RARE’s Genglycos for GSD1a is a positive read for SPRB as TA-ERT approaches next quarter’s BLA submission.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.